| Age (years; mean ± SD) |
69.1 ± 4.3 |
66.8 ± 10.3 |
0.485057 |
| Gender (no.; Male: Female) |
5: 7 |
25: 11 |
0.08519 |
| HbA1c (%) |
7.5 ± 1.5 |
8.2 ± 1.2 |
0.344098 |
| Pre-treatment BCVA at visit 1 |
69.6 ± 14.3 |
66.7 ± 16.2 |
0.585873 |
| (ETDRS letters; mean ± SD) |
| BCVA at visit 2 |
69.6 ± 14.2 |
69.2 ± 13.3 |
0.931332 |
| (ETDRS letters; mean ± SD) |
| BCVA at visit 3 |
69.1 ± 14.5 |
68.8 ± 13.4 |
0.956494 |
| (ETDRS letters; mean ± SD) |
| BCVA at visit 4 |
67.3 ± 16.3 |
71.8 ± 14.0 |
0.359004 |
| (ETDRS letters; mean ± SD) |
| Improvement BCVA |
-2.3 ± 4.4 |
5.1 ± 7.7 |
0.003007 |
| (ETDRS letters; mean ± SD) |
| Pre-treatment CRT at visit1 |
373 ± 139 |
389 ± 129 |
0.725201 |
| (μm; mean ± SD) |
| CRT at visit 2 (μm; mean ± SD) |
363 ± 145 |
295 ± 112 |
0.0968551 |
| CRT at visit 3 (μm; mean ± SD) |
387 ± 133 |
275 ± 129 |
0.0125176 |
| CRT at visit 4 (μm; mean ± SD) |
381 ± 140 |
253 ± 111 |
0.0023279 |
| Improvement CRT rate |
-4.7 ± 23.3 |
32.9 ± 20.4 |
0.00000286569 |
| (%; mean ± SD) |
| Pre-treatment IOP |
14.7 ± 3.5 |
14.8 ± 3.2 |
0.879601 |
| (mmHg; mean ± SD) |
